AzarGen And iBio Push On With Plant-Based Rituximab
Biosimilar Development Aimed Towards African Continent
Executive Summary
AzarGen and iBio have advanced their alliance, with the latter revealing it would now begin manufacturing and characterizing additional supplies of plant-based rituximab, to enable pre-clinical studies comparing it with Roche’s MabThera original.